Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06101134 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion moved earlier from Feb 26, 2027 to Dec 21, 2026 Completion moved earlier from Aug 31, 2027 to Feb 26, 2027v26 Show 1 more changeShow less
    • Completion moved earlier from Aug 31, 2027 to Feb 26, 2027
  2. Completion date: Aug 31, 2027 to Feb 26, 2027v25
  3. Results first posted: Apr 9, 2026v24
  4. Primary endpoint revised Secondary endpoints: 9 to 2v23 Show 1 more changeShow less
    • Secondary endpoints: 9 to 2

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date changed from estimate of Aug 29, 2025 to Apr 10, 2025v22
Show 20 earlier versionsHide 20 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Study sites: 37 to 31v21 Show 1 more changeShow less
    • Study sites: 37 to 31
  2. Study sites revised (37)v20 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 2 of 37 sitesv19
  4. Study sites revised (37)v18 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 35 to 37v17
  6. Site details revised at 1 of 35 sitesv16
  7. Study sites revised (35)v15 See this version in full on ClinicalTrials.gov ↗
  8. Start date: Nov 8, 2023 to Nov 6, 2023 Study sites revised (35)v14 Show 1 more changeShow less
    • Study sites revised (35)

    See this version in full on ClinicalTrials.gov ↗

  9. Start date: Nov 6, 2023 to Nov 8, 2023 Study sites revised (35)v13 Show 1 more changeShow less
    • Study sites revised (35)

    See this version in full on ClinicalTrials.gov ↗

  10. Start date: Nov 8, 2023 to Nov 6, 2023 Study sites revised (35)v12 Show 1 more changeShow less
    • Study sites revised (35)

    See this version in full on ClinicalTrials.gov ↗

  11. Study sites revised (35)v11 See this version in full on ClinicalTrials.gov ↗
  12. Study sites revised (35)v10 See this version in full on ClinicalTrials.gov ↗
  13. Study sites revised (35)v9 See this version in full on ClinicalTrials.gov ↗
  14. Study sites revised (35)v8 See this version in full on ClinicalTrials.gov ↗
  15. Study sites: 34 to 35v7
  16. Study sites: 33 to 34v6
  17. Re-verified, no change to tracked fieldsv5
  18. Site details revised at 3 of 33 sitesv4
  19. Study sites: 30 to 33 Start date: Nov 6, 2023 to Nov 8, 2023v3 Show 1 more changeShow less
    • Start date: Nov 6, 2023 to Nov 8, 2023
  20. Trial status: Not Yet Recruiting to Recruiting Study sites: 29 to 30 · Start date changed from estimate of Dec 29, 2023 to Nov 6, 2023v2 Show 2 more changesShow less
    • Study sites: 29 to 30
    • Start date changed from estimate of Dec 29, 2023 to Nov 6, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bristol-Myers Squibb
312 trials monitored
See 13 trials at risk
Melanoma
1,026 trials monitored
See 48 trials at risk
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
Trial Details
NCT Number NCT06101134
Lead Sponsor Bristol-Myers Squibb
Conditions Melanoma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov